Abstract:Proteolysis-targeting chimeras (PROTACs) are essential bifunctional molecules that target proteins of interest (POIs) for degradation by cellular ubiquitination machinery. Despite significant progress made in understanding PROTACs' functions, their therapeutic potential remains largely untapped. As a result of the success of highly flexible, scalable, and low-cost mRNA therapies, as well as the advantages of the first generation of peptide PROTACs (p-PROTACs), we present for the first time an engineering mRNA PROTACs (m-PROTACs) strategy. This design combines von Hippel-Lindau (VHL) recruiting peptide encoding mRNA and POI-binding peptide encoding mRNA to form m-PROTAC and promote cellular POI degradation. We then performed proof-of-concept experiments using two m-PROTACs targeting two cancer-related proteins, estrogen receptor alpha and B-cell lymphoma-extra large protein. Our results demonstrated that m-PROTACs could successfully degrade the POIs in different cell lines and more effectively inhibit cell proliferation than the traditional p-PROTACs. Moreover, the in vivo experiment demonstrated that m-PROTAC led to significant tumor regression in the 4T1 mouse xenograft model. This finding highlights the enormous potential of m-PROTAC as a promising approach for targeted protein degradation therapy. We developed mRNA proteolysis-targeting chimeras (PROTACs), a novel type of PROTACs, which incorporate mRNAs encoding E3 ligase recruiting peptide ligand and protein of interest (POI)-binding peptide ligand to promote cellular POI degradation. For the first time, we demonstrated that the encoding peptide PROTACs could degrade POIs and inhibit cell proliferation more effectively than the traditional peptide PROTACs, indicating their tremendous potential for targeted protein degradation therapy. image

The aptamer-based RNA-PROTAC

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Inhibition of RNA-binding proteins with small molecules

Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins

Mrna PROTACs: Engineering PROTACs for High‐efficiency Targeted Protein Degradation

PROTACs: New method to degrade transcription regulating proteins

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

mRNA PROTACs: engineering PROTACs for high-efficiency targeted protein degradation

RNA-Binding Proteome Analysis and Functional Explorations

Rationally designed inhibitors of the Musashi protein-RNA interaction by hotspot mimicry

Targeted Biomolecule Regulation Platform: A Split-and-Mix PROTAC Approach

Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs

Inducible Degradation of Oncogenic Nucleolin Using an Aptamer-Based PROTAC

Engineering Reprogrammable RNA-binding Proteins for Study and Manipulation of the Transcriptome

Revealing the hidden RBP-RNA interactions with RNA modification enzyme-based strategies

Cooperatively Designed Aptamer-PROTACs for Spatioselective Degradation of Nucleocytoplasmic Shuttling Protein for Enhanced Combinational Therapy

Targeted Degradation of DNA/RNA Binding Proteins Via Covalent Hydrophobic Tagging

Developments of CRBN-based PROTACs as potential therapeutic agents

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

TF-PROTACs Enable Targeted Degradation of Transcription Factors.